Abstract 14P
Background
Homologous recombination deficiency (HRD) is a clinically-proven indicator of sensitivity against platinum-based chemotherapy and PARP inhibitors in various malignancies, including ovarian cancers. Until now, HRD prediction has been carried out by detecting the deleterious mutations of the BRCA1 or BRCA2 gene or measuring genomic scar, i.e., scarHRD. However, the scarHRD method has limitations in applying tumors without matched germline data. Investigating HRD-specific transcriptomic signatures is one of the tangible approaches to predicting HRD in tumor-only samples. Although several RNA-seq-based HRD prediction algorithms have been developed, they support mainly cohort-wise classification regarding HRD status yet do not provide an equivalent value to scarHRD. The transformation into scarHRD from transcriptomic data would be highly valuable for clinical application and research use.
Methods
Here, we developed an algorithm of transcriptome-based HRD analysis, i.e., expHRD. The prediction model was established using the elastic net in TCGA-pan cancer training set. HRD geneset for applying expHRD calculation using single-sample geneset enrichment analysis was derived by bootstrap technique.
Results
expHRD is a clinically applicable RNA-seq-based HRD prediction platform in tumor-only samples. In clinic, expHRD can provide supportive information for predicting platinum or PARP inhibitor responses by providing predicted scarHRD score. We could extract the expHRD to analyze the inter-cohort evaluation, HRD-associated gene expression profile, mutations, or tumor types in samples without matched germline data, such as cryopreserved or formalin-fixed tissues, cell lines, or organoids.
Conclusions
Developing a targeted transcriptomic panel for calculating expHRD would be a cost-effective approach to linking our platform with the clinic.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract